/ Not yet recruitingPhase 2 A randomized, double-blind, placebo-controlled, parallel group study toevaluate the safety and efficacy of four weeks treatment of 7.5 mgb.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation powder,hard capsule for Handihaler®) in patients with COPD associated withchronic bronchitis. - Safety and efficacy of four weeks BIBW 2948 BS in COPD patients with chronic bronchitis
/ Not yet recruitingPhase 2 A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders.
/ Not yet recruitingNot Applicable A placebo controlled trial of alteplase (rt-PA) in acute ischemichemispheric stroke where thrombolysis is initiated between 3 and 4hours 30 minutes after stroke onset - ECASS III
100 Clinical Results associated with Boehringer Ingelheim France SASU
0 Patents (Medical) associated with Boehringer Ingelheim France SASU
100 Deals associated with Boehringer Ingelheim France SASU
100 Translational Medicine associated with Boehringer Ingelheim France SASU